Summit Therapeutics (SMMT) Operating Margin (2016 - 2024)
Historic Operating Margin for Summit Therapeutics (SMMT) over the last 6 years, with Q3 2022 value amounting to 7700.0%.
- Summit Therapeutics' Operating Margin changed N/A to 7700.0% in Q3 2022 from the same period last year, while for Dec 2024 it was 2903.65%, marking a year-over-year increase of 5.5651520379798105e22%. This contributed to the annual value of 10225.39% for FY2022, which is 54611000.0% down from last year.
- Per Summit Therapeutics' latest filing, its Operating Margin stood at 7700.0% for Q3 2022.
- Summit Therapeutics' 5-year Operating Margin high stood at 64.53% for Q3 2018, and its period low was 7700.0% during Q3 2022.
- In the last 4 years, Summit Therapeutics' Operating Margin had a median value of 1507.33% in 2019 and averaged 2578.18%.
- In the last 5 years, Summit Therapeutics' Operating Margin surged by 1621200bps in 2018 and then plummeted by -49526300bps in 2019.
- Quarter analysis of 4 years shows Summit Therapeutics' Operating Margin stood at 1385.05% in 2018, then tumbled by -348bps to 6205.65% in 2019, then surged by 62bps to 2343.08% in 2020, then crashed by -229bps to 7700.0% in 2022.
- Its last three reported values are 7700.0% in Q3 2022, 2343.08% for Q1 2020, and 6205.65% during Q4 2019.